Method Development With the Intention of Minimizing OOS Results

Instructor: Dr. Wise Blackman
Product ID: 700219
Training Level: Advanced
  • Duration: 60 Min

recorded version

1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section

Training CD

One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-963-2556


Read Frequently Asked Questions

In this OOS (Out of Specification) training guidance will be provided in developing assays that will meet specifications thus reducing OOS and OOT results.

Attention to parameters that may be difficult to control or require trending to insure appropriate values are consistently met is necessary during the early development phase. A good development plan will allow full investigation of these parameters.

What Attendees will Learn:

  • The importance of cell-based potency assays
  • Specifics of assay performance
  • Defining the control chart
  • Identifying data to enter into the control chart
  • Monitoring the process
  • Establishing limits and defining actions and alerts

Who Will Benefit:

  • Importance of defining the method and trending necessary information
  • Specifics of assay performance
  • Using the control charts in method development
  • Setting prelimnary specifications

Instructor Profile:

Dr. Wise-Blackman, is currently Senior Manager, Cellular Technologies, at the Cardinal Health RTP-Bio site. Dr. Wise-Blackman leads a team that successfully develops, optimizes, validates, and performs cell-based assays for lot release and stability projects in a GxP environment She was the co-recipient of both the Customer Focus Award for 3rd Quarter FY2004 and the Presidents Award for FY2004. Her expertise is GMP bioassays to support release and stability testing of biotechnology products, GLP ELISA assay development and validation, Cell Based Screens, and Receptor Binding Assays. Dr. Wise-Blackman was previously employed at Dupont Pharmaceuticals for nine years, working in the cardiovascular pharmacology and high throughput screening departments. She received her Ph.D. in Pharmacology from the University of Virginia, Charlottesville, VA and her Bachelor of Science in Biology from the Massachusetts Institute of Technology, Cambridge, MA

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
21 CFR Part 11 Compliance for SaaS/Cloud Applications - 80202SEM

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed